12:00 AM
 | 
Jul 20, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Perifosine: Phase I started

Keryx began an open-label, dose-escalation, U.S. Phase I trial to evaluate perifosine in up to 24 pediatric patients. The company has North American rights to perifosine from Aeterna...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >